Barilla Confirmed as the World’s Leading Food Company for Reputation - Ranking 9th Overall Globally
8.4.2026 14:42:00 CEST | Business Wire | Press release
GLOBAL REPTRAK®100 2026For the third consecutive year, Barilla is confirmed as the world’s leading food company in the Global RepTrak® 100 and enters the overall Top 10 of global companies.The Group ranks 9th overall, up 16 positions compared to 2025.
For the third year in a row, Barilla is confirmed as the world’s leading company in the food sector for reputation in the Global RepTrak® 100 ranking conducted by RepTrak, which since 1999 has annually analyzed the companies with the strongest reputations worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260407912080/en/

In the 2026 ranking, the Group reaches 9th place overall, moving up 16 spots compared to 2025 (ranked at 25th) and entering the global Top 10, confirming the company’s steady reputation‑building journey developed over the years. This result reflects Barilla’s ability to combine product quality, industrial vision and social responsibility – factors that are increasingly central to the assessment of corporate reputation. The study evaluates key elements including performance, innovation, governance, sustainability and the ability to generate long‑term trust.
“In today’s turbulent macroeconomic environment, maintaining stable performance is already a positive signal,” states Sara Fargion, Vice President RepTrak, EMEA. “However, the ability to grow in this context becomes a true differentiator. The Food sector, in particular, is facing significant pressure, as ongoing waves of inflation continue to drive intense media scrutiny and shape public perception consistently across all 14 countries where we measure reputation.”
Present in over 100 countries, with 30 production sites and an annual output exceeding 2 million tons across pasta, ready‑made sauces and bakery products, Barilla continues to invest in innovation and the continuous improvement of its product offering.
This commitment is reflected in the inauguration in November, in Parma, of BITE (Barilla Innovation & Technology Experience), the new research and development center where 200 professionals – including food technologists, researchers, engineers and food designers – develop new products and improve recipes, production processes and packaging. BITE is a state‑of‑the‑art hub that integrates scientific expertise, food culture and technology to design the future of food, supported by an open‑innovation ecosystem involving universities and research centers worldwide, accelerating the development of increasingly sustainable, safe solutions aligned with evolving consumer needs.
Further confirming its ability to respond to consumer expectations, the Group has been recognized in recent years with two awards from the Product of the Year program in Italy: in 2025, Barilla Al Bronzo was awarded in the Pasta category, while in 2026 the recognition went to Barilla Protein+, both selected by more than 12,000 consumers as part of research conducted by Circana.
Barilla Group’s growth and its ability to engage with new food trends and cultures are also supported by its partnership with Formula 1®, which has brought Barilla’s core value of togetherness into the world’s premier motorsport competition. Globally, high‑impact social initiatives with organizations – such as The Food Bank and Doctors Without Borders – have mobilized thousands of volunteers and citizens, supporting social and humanitarian projects through tangible acts of participation and sharing.
At the same time, Barilla continues to advance its social and environmental commitments, integrating sustainability and energy and water efficiency at the core of its growth model. As part of this ongoing effort, in 2024, the total volume of water recycled and reused increased by 45% compared to 2022, with an even more significant improvement in water‑stressed areas, where the increase reached 164%. This commitment also extends to Barilla’s nearly 9,000 people – the true driving force behind the Group’s performance – and includes, among other initiatives, a global gender‑neutral parental leave policy guaranteeing 12 fully paid weeks for both parents, as well as the achievement, since 2020, of global gender pay equity in line with the principle of “equal pay for equal work” for all Barilla employees worldwide.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260407912080/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom